Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.

Revenue
+58.0%
EPS
+112.2%
Free cash flow
+411.2%
Total debt
−2.25%

Quarter to September 2026, against a year earlier

224.21 4.23 +1.92%
Market cap
$13.0B
P/E
0.0×
Fwd P/E
−803×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a

Glaukos Corporation 10-Q filed Oct 28, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 5:22 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Oct 31, 2025: 20 added · 27 removed · 54 modified; 4 with only figures updated; 1 moved without change